Granules India Limited is a large-scale vertically integrated Company founded in 1991 manufacturing Active Pharmaceutical Ingredient (API), Pharmaceutical Formulation Intermediate (PFI) and Finished Dosage (FD). The Company over the years has created a strong presence in ‘the first line of defence’ products such as Paracetamol, Ibuprofen, Metformin, Methocarbamol, and Guaifenesin.

The company’s product-focused, vertically integrated business model has created a leadership position in several generic drugs. It has a strong presence in ‘first line of defence’ products, including Paracetamol, Ibuprofen, Guaifenesin and Metformin. It exports nearly 60% of its revenue to the US and Europe. Its key customers include some of the leading generic, as well as, branded pharmaceutical companies. Its integrated model for manufacturing APIs, PFIs and Finished Dosages enables it to provide products across the value chain and enhances its competitiveness. It has emerged into a knowledge driven, R&D focused, multi-product organization, with inherent strength in efficient manufacturing of high-volume pharmaceutical products.

Business area of the company

Granules India is one of the vertically integrated, high-growth pharmaceutical manufacturing company in India today. Based out of Hyderabad, India, it is into manufacturing Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediaries (PFIs) and Finished Dosages (FDs).

Granules India Ltd.

Eris Lifesciences Ltd.

Astrazeneca Pharma India Ltd.

Medplus Health Services Ltd.

Natco Pharma Ltd.

Procter & Gamble Health Ltd.

Jubilant Pharmova Ltd.

Suven Pharmaceuticals Ltd.

Glenmark Pharmaceuticals Ltd.

Caplin Point Laboratories Ltd.

Alembic Pharmaceuticals Ltd.

Glenmark Life Sciences Ltd.

Sanofi India Ltd.

FDC Ltd.

Aarti Drugs Ltd.

HDFC Bank Ltd.

ICICI Bank Ltd.

ITC Ltd.

Reliance Industries Ltd.

Tata Motors Ltd.

Market Cap	8,767 Cr		EPS	20.0		High	360.4
Stock P/E	18.1		Net Profit Margin	12.5		Low	356

GRANULES